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practice patterns. CONCLUSIONS: The interviews allowed to extrapolate European
findings to the Asia-Pacific region and therefore improved the validity of the cost-
effectiveness models developed for these countries. In our opinion, this method-
ology represents an acceptable alternative whenmore time-consuming and costly
chart reviews cannot be repeated in multiple countries. The significant economic
burden of OAG was confirmed.
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OBJECTIVES: Topical prostaglandin analogues are safe and effective to treat ocular
hypertension (OHT) and open-angle glaucoma (OAG). The preservatives used in
prostaglandin, however, drops increase the short- to long-term risk of developing
ocular surface disease (OSD). We aimed to compare the 10-year costs and clinical
outcomes with Polyquad®-preserved travoprost to costs and outcomes with ben-
zalkonium chloride (BAK)-preserved prostaglandins in 7 Asian countries.
METHODS: A semi-Markov health economic model was developed. Treatment-
naïve OHT/OAG patients were initiated on treatment with Polyquad®-travoprost,
latanoprost or bimatoprost (1st line) with possible timolol adjunct (2nd line, fixed
combination). The literature provided information on the increased risks of treat-
ment change andOSDdevelopment due to exposure to BAK, and disease evolution.
Further treatment lines, including eye laser/surgery, and other medical resource
usewere obtained using data fromaGermanobservational study (COGIS) thatwere
validated and adapted in each country by clinical experts. Local unit costs were
collected and applied to each resource (All-Payer perspective, 2011 costs). Country-
specific discounting was used. RESULTS: Compared to BAK-preserved prostaglan-
dins, Polyquad-travoprost was dominant (15% less OSD; total costs reductions vs.
latanoprost in Singapore14%, India andMalaysia13%, South Korea9% and vs.
bimatoprost from 2% in Thailand to 19% in South Korea), or else cost-effective
(incremental cost-effectiveness ratios 1,000US$ per OSD-free year gained). In
each country, the estimated reductions in glaucoma medical (non-drug) manage-
ment costs (range from18 to22%), and total OSD costs (from25 to27%), were
significant as per second-order sensitivity analysis. As a long-term consequence of
the modeled lower persistence and impaired compliance the presence of OSD was
associated with higher total costs. CONCLUSIONS: This multi-country model esti-
mated that treating Asian OHT/OAG patientswith Polyquad®-preserved travoprost
would generate significantly less OSD compared to BAK-preserved prostaglandins,
together with savings on glaucoma and OSD management costs.
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OBJECTIVES: Prostaglandin analogues are approved as a first-line treatment of
ocular hypertension (OHT) and open-angle glaucoma (OAG). Existingmolecules are
often preserved with benzalkonium chloride (BAK), which is known to create dry
eye. We aimed to assess the long-term impact of the type of preservative used in
prostaglandins on OHT/OAG treatment outcomes and costs in Hong Kong.
METHODS: A semi-Markov model was developed to evaluate the 10-year dry eye
rate andmanagement costs of OHT/OAG patients initiating a treatmentwith either
Polyquad®-preserved travoprost or latanoprost and bimatoprost (both BAK-pre-
served). The probability of experiencing dry eye was obtained from literature.
Switch rates to surgical or medical treatment were taken from UK/US health care
databases. Local unit costs (‘All-payer’ perspective, 2011 private and public tariffs)
were applied to the medical resources collected in a German retrospective chart
review, re-assessed and adapted to the local practice by 3 clinical experts. Discount
rate was 3% for costs and outcomes. A second-order sensitivity analysis provided
95% confidence intervals. RESULTS: The 10-year clinical and economic outcomes
were significantly improved with travoprost compared to BAK-preserved latano-
prost: dry eye rate decreased from 53% [45;59%] to 35% [31;38%], the proportion of
patients reaching a 3rd line treatment from 85% [80;88%] to 57% [44;68%], the sur-
gery rate dropped from 3.0% [2.4;3.5%] to 1.3%.[0.6;1.8%] while the total costs were
significantly reduced by 25% (private setting) and 29% (public setting) vs. latano-
prost, mostly due to a 33% reduction in glaucoma non-drugmanagement cost. The
benefits vs. bimatoprost were similar. The impact of the presence of OSD on costs
was sizeable, and the treatment switch rate was an important cost driver.
CONCLUSIONS: This model suggests a favorable impact of using travoprost rather
than BAK-preserved prostaglandins on 10-year clinical outcomes, which generates
savings on total costs (20-30%) due to reduced medical management costs.
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OBJECTIVES: Safety and efficacy of tafluprost for open-angle glaucoma or ocular
hypertension (OH) have been proven in clinical trials. While tafluprost and latano-
prost have similar efficacy, the absence of the preservative benzalkonium chloride
(BAK) in tafluprost may make it a preferred alternative for patients who are intol-
erant to BAK (i.e., reduces adverse ocular symptoms such as irritation and dry eye).
Reduced ocular symptoms offer clinical/QoL benefits and cost savings associated
with less rescue medication use (artificial tears). Further, the single-dose unit for-
mulation of tafluprost is predicted to lessenmedicationwastage and thus generate
cost savings versus latanoprost (dispensed in multi-dose bottles). These cost-sav-
ings are quantified and cost-effectiveness ratios are calculated in the current study.
METHODS: Resource usage and associated costs are quantified to determine cost
savings offered by tafluprost over latanoprost. Disutility fromadverse ocular symp-
toms caused by preservatives is also determined via a systematic review of litera-
ture to transform tafluprost’s superior tolerability to QALYs. The perspective of this
analysis is the Australian health care system. RESULTS: Preservative-free taflu-
prost was shown to be a highly cost-effective, most likely dominant, strategy over
preserved latanoprost. The likely cost savings due to reducedmedication wastage,
informed by the pattern of latanoprost utilisation observed in the Australian drug
reimbursement system (PBS), in itself wouldmake tafluprost a cost-saving strategy
versus latanoprost. The available evidence suggested that 47.6% of patients on
preserved latanoprost experience some adverse ocular symptoms, while this is
expected to be 29.0%with preservative-free tafluprost. Average cost savings attrib-
utable to reduced artificial tear use was estimated to be $23.64 per patient per year.
This superior tolerability is also estimated to produce an incremental QALY of
0.0107 for preservative-free tafluprost each year when compared with preserved
latanoprost. CONCLUSIONS: Preservative-free tafluprost is a highly cost-effective,
most likely dominant, strategy over preserved latanoprost.
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OBJECTIVES: To investigate the cost-effectiveness of a hypothetical community
screening and subsequent treatment programme for glaucoma in comparisonwith
current practice (i.e. with no screening programme but with some opportunistic
case finding), in both urban and rural areas of India.METHODS: A decision analyt-
ical model was built to model events, costs and treatment pathways with and
without a hypothetical screening programme for glaucoma for a population aged
between 40-69 years age in urban and rural areas. The treatment pathway included
both primary open-angle glaucoma and angle closure disease. Screening and treat-
ment costs were obtained from an administrator of a tertiary eye hospital in India.
The probabilities for each pathway (i.e. for urban and rural areas) were derived
from published literature and expert opinion (Glaucoma specialist currently prac-
ticing in India). The glaucoma prevalence rates for urban and rural areas were
adapted from the Chennai Glaucoma Study findings. Separate decision analytical
models for urban and rural areaswere built for calculating the cost-effectiveness of
community screening for glaucoma in comparison to current practice (i.e. no
screening programmewith some opportunistic case finding). The outcomes calcu-
lated were the incremental cost of screening (i.e. compared with no screening), the
additional cases treated with screening; and the cost per QALY gained by
screening. RESULTS: The introduction of a community screening programme for
glaucoma is likely to be cost-effective, the estimated ICER values beingx 8312.71 for
urban areas and x 7292.30 for rural areas, when compared with no screening pro-
gramme. The community screening for glaucoma would treat an additional 4443
cases and 2872 cases, and prevent 1790 person-years of blindness, and 1150 per-
son-years of blindness over a 10-year period, in urban and rural areas respectively.
CONCLUSIONS: If adequate resources (trained medical personnel and equipment)
is available the likelihood of community screening for glaucoma to be cost-effec-
tive and have an impact on reducing glaucoma-related blindness burden, remains
high in India.
SENSORY SYSTEMS DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
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OBJECTIVES: To quantify the health burden associated with vision problems in
Singaporean Malays and Indians, using the EQ-5D health index. METHODS: The
Singapore Malay Eye Study (SiMES) and the Singapore Indian Eye Study (SINDI)
were population-based studies of 3,259 Malays (mean age: 59 years; range: 40 to 80;
male: 48.1%) and 3,397 Indians (mean age: 58 years; range: 43 to 84; male: 50.2%),
respectively. Each participant was given a comprehensive eye assessment and
answered the EQ-5D questions. The impact of presenting bilateral visual impair-
ment and 5 major eye conditions (i.e. age-related macular degeneration (AMD),
glaucoma, cataract, diabetic retinopathy, and refractive error) on the EQ-5D health
index score was estimated using separate linear regression models. According to
USdefinition, lowvision is defined as 0.30LogMAR1.00 and blindness as LogMAR
1.00. RESULTS: After adjusted for age, gender and co-morbidities, Singapore Ma-
lays with low vision in one eye and normal vision in the other eye (difference:
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0.02, p0.042), low vision in both eyes (difference:0.02, p0.041), and blindness
in both eyes (difference: 0.10, p0.0001) had lower EQ-5D score than those with-
out visual impairment. Singapore Indians with low vision in both eyes (difference:
0.03, p0.0081), low vision in one eye and blindness in the other eye (difference:
0.09, p0.0001), and blindness in both eyes (difference: 0.16, p0.0004) had
lower EQ-5D score than those without visual impairment. After adjusted for age,
gender and co-morbidities, none of the 5 eye conditions was associated with re-
duction in EQ-5D scores inMalays or Indians, except that Indianswith cataract had
lower EQ-5D scores than those without cataract (difference: 0.02, p0.0431).
CONCLUSIONS: Health burden is associated with visual impairment, but not with
the presence of the eye conditions. Vision problems pose more health burden to
Indians than Malays in Singapore.
URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies
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OBJECTIVES: To evaluate the effect of aqueous extract of Boswellia serrata Roxb
oleo gumon urinary electrolytes, pH and diuresis in normal albino rats.METHODS:
Oleo gumweighing 500g was soaked in hot boiling water (1L) at room temperature
for 3 days with occasional shaking. Filtrate was evaporated on rotary evaporator
under reduced pressure (760 mmHg) to a thick, semi-solid pasty mass of dark
drown color that was completely solubilized in both distilled water and normal
saline for in-vitro and in-vivo experimentation. Phytochemical analysis was car-
ried out for alkaloids, saponins, anthraquinones, flavanoids and tannins. For in-
vivo activity, five groups of with six animals in each were administered normal
saline (10ml/Kg, i.p.), Furosemide (10mg/kg) and crude extracts of Boswellia sarrata
(10, 30 and 50mg/kg of body weight), respectively. Toxicological effect of plant was
undertaken in rats at a dose of 3000mg/kg. Data was expressed asmean SEM and
analyzed using Graph Pad Prism (Graph PAD, San Diego, USA). Student t-test was
applied for data analysis. p values 0.05 were considered significant. RESULTS:
Phytochemical screening of Boswellia serrata Roxb confirmed the presence of sa-
ponins and flavonoids. Furosemide induced significant diuresis and electrolytes
(Na&K) excretionwhile plant extracts increased urinary output and electrolytes
excretion in a dose-dependentmanner. Diuretic index of test groupswere1.36, 2.06
and 2.9, respectively while, Lipschitz value also confirmed diuretic activity in dose
dependent manner. Urinary pH remained unchanged during the course of the
study whereas, no lethality was observed at the dose of 3000mg/kg.
CONCLUSIONS: Aqueous Boswellia serrata oleo gum extracts administered partic-
ularly at the dose of 50mg/kg significantly induced water and electrolytes with no
signs of toxicity.
URINARY/KIDNEY DISORDERS - Cost Studies
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OBJECTIVES: To assess economic burden associated with hemodialysis (HD) and
continuous ambulatory peritoneal dialysis (CAPD) among patients with end-stage
renal disease (ESRD) and treated in a tertiary hospital in China. METHODS: From
Sept 2004 to Jan 2005, adult patients on HD or CAPD for at least 6 months were
recruited. Resource utilization and costs were collected by medical records review
and patient survey. The economic burden was divided into direct costs including
medical (dialysis, drugs, lab, and inpatient) and nonmedical (transportation, hired
caregivers, and special nutritional products) and indirect costs due to productivity
loss (human capital approach). The annualized costs expressed in 2010 Yuan(¥)
were analyzed using Wilcoxon test and General Linear Model with gamma distri-
bution and log link. RESULTS: Eighty-six patients [50 on CAPD and 36 on standard
HD (3x4-hour weekly)] were included for the analysis, with 55% male and a mean
age of 57.715.6 years. No differences were found in age, sex, education, payment
method, income, originating disease, haemoglobin level, and dialysis time be-
tween HD and CAPD. Mean(SD)/Median of annual medical expenses were
¥91,476(42,935)/¥82,478 for HD and ¥68,898(11,698)/¥68,191 for CAPD (p0.0001);
nonmedical direct expenses were ¥5,883(4,256)/¥4,780 for HD and ¥3,041(3,835)/
¥1,300 for CAPD (p0.0001). No differencewas found in indirect costs [¥3,167 (6,992)
for HD and ¥5,064 (8,354) for CAPD (p0.3)]. Total annual costs were
¥100,403(44,419)/¥90,262 for HD and ¥79,859(22,210)/¥77,681 for CAPD (p0.001).
Controlling for key factors/covariates, HD patients incurred 16% higher total cost
compared to CAPD patients (p0.01). Patients with younger age (p0.005), public
health insurance (p0.0001), or originating disease of diabetes (p0.03) incurred
higher total costs compared to their counterparts, respectively. CONCLUSIONS:
Patients received HD incurred more direct costs compared to patients undergoing
CAPD. The findings of this study may help understand the disease burden and
establish cost-effective treatment modalities in ESRD from Chinese societal per-
spective.
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OBJECTIVES: To evaluate the annual health expenditure (AHE) in patients with
neurogenic detrusor overactivity (NDO) after spinal cord injury (SCI). METHODS:
Data containing 2 million randomly sampled individuals from the National Health
Insurance Research Database (NHIRD) in Taiwan were used. Patients with emer-
gency department visits or hospitalizations for SCI defined by ICD-9 codes 806.X
and 952.X between 2006 and 2008 were retrieved. NDOwas defined by: 1) diagnosis
defined by ICD-9 codes 596.5 and 788.3 (excluding 596.53, paralysis of bladder); 2)
pharmacological treatment for neurogenic voiding dysfunction and urinary symp-
toms such as alpha blockers, antimuscarinic agents, and cholinergic agents; and 3)
procedures such as indwelling or intermittent catheterization defined byNHI codes
47,013C and 47,014C. All patients were followed for one year. The total AHE, as well
as three subcategories, hospital, outpatient, and pharmacological treatment re-
lated cost were calculated respectively. Covariates including patient’s demograph-
ics, hospital length of stay, concomitant medications, and comorbid conditions
were considered in the final linear regression to compare the AHE between NDO
and non-NDO group. RESULTS: A total of 941 eligible individuals with SCI were
identified from 2006 to 2008, of whom 165 (17.5%) were NDO cases with amean age
of 54 and consisting of 64%male. The total AHEwas 494,325 (499,259) and 108,529
(147,287) N.T. dollars inNDO and non-NDO group, respectively. After adjusting by
regression model, the total AHE was higher in NDO (364,611; SE21,082;
p0.001) than non-NDO group. Higher AHE was also shown in NDO in each sub-
category when comparing with non-NDO. CONCLUSIONS: A significant impact on
the financial burden of NDO was shown in this study. Higher AHE associated with
NDOmay also reflective of the higher severity of SCI or other comorbid conditions.
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OBJECTIVES:To estimate the total economic burden of both peritoneal dialysis and
renal anemia treatment in China. METHODS: Eight medical centers with regular
follow-up system for peritoneal dialysis patients in 6 provinces were selected for
prospective observation research. Inclusion and exclusion criteria were set down
before the study through the discussion with clinical experts. Patients had been
recruited in the study since July of 2011. Patient baseline characteristics, treatment
and expenditure for both outpatient and inpatient during 3-months follow-up du-
ration were recorded. Direct medical costs included fee for registration and ser-
vices, medical examination, drugs andmedical consumable materials. Direct non-
medical costs included transportation fee and nursing fee. Off-work days were
collected to estimate indirect costs.RESULTS:A total of 149 patientswith records of
703 outpatient visits and 19 inpatient stays were collected. Mean age of patients is
50.9with averagely 3.47 years of peritoneal dialysis treatment and 3.35 years of EPO
treatment. The average frequencywas 1.41 visits inmedical centers permonth and
1.23 visits in community health centers. The average cost of EPO was CNY1,518
(US$241) per month with average dosage of 16443IU. Total economic burden per
peritoneal dialysis patient was CNY9,756 (US$1,549) per month, including
CNY9,163 (US$1,454) for direct medical costs, CNY210 (US$33) for direct non-med-
ical costs and CNY383 (US$61) for indirect costs. The share of total economic bur-
den related to GDP per capita ranged from 1.3 times to 6.4 times in 6 sampling
provinces. CONCLUSIONS: The total economic burden of both peritoneal dialysis
and renal anemia treatment seems relatively high, which needs more attention
from the government and society.
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OBJECTIVES: This study evaluated the clinical and economic impacts of clinical
pharmacy education (CPE) on infection management among patients with chronic
kidney disease (CKD) stage 4 and 5 in Haji Adam Malik (HAM) hospital, Indonesia.
METHODS: A quasi-experimental economic evaluation comparing CPE impact on
six-months CKD mortality was conducted based on payer perspective. The exper-
imental group (n63) received care by health care providers that were given CPE on
DRPs and dose adjustment. The control group (n80) was based on the historical
cohort of patients that received care before the CPE. Measure of clinical outcome
applied in this study was number of lives saved/100 patients treated. Cost-effec-
tiveness (CE) ratios for stage 4 and 5 CKD patients without CPE and with CPE,
incremental cost effectiveness ratios (ICERs) for stage 4 and 5 CKD patients were
analyzed. RESULTS: Lives saved (%) in the treatment of CKD without CPE: CKD
stage 4, 78.57; CKD stage 5, 57.58. Lives saved (%) in the treatment of CKDwith CPE:
CKD stage 4, 88.89; CKD stage 5, 65.45. Cost- effectiveness ratios for stage 4 without
and with CPEs were Rp3,593,295.97 and Rp3,348,733.27, respectively. Cost-effec-
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